@article{a41694dca1ea4e8a93b65d1b7006ef70,
title = "The critical care research networks experience",
abstract = "Neurocritical care is a subspecialty of critical care medicine, dedicated to the care and the advancement of care of critically ill patients with neurosurgical or neurological diseases. Neurocritical care patients are heterogeneous, in both their disease process and the therapies they receive, however, several studies demonstrate that care of these patients in dedicated NeuroIntensive Care Units (neuroICUs) by neurointensivists, who coordinate their care is associated with reduced mortality and resource utilization. NeuroICUs foster innovation, and yet despite all the recent advances, much research needs to be undertaken in neurocritical care to better understand the disease pathophysiology and to demonstrate improved outcome with the use of goal-directed therapy based on evolving techniques and therapies.",
keywords = "ANZICS, ARDSNET, NETT, Neurocritical care, Research networks",
author = "{Le Roux}, {P. D.} and J. Cooper and Guntupalli, {K. K.} and R. Silbergleit and J. Daily and R. Geocadin and Wijman, {C. A.C.} and Suarez, {J. I.}",
note = "Funding Information: The mission of NETT is to improve the outcome of patients with acute neurological problems through innovative research focused on the emergent phase of patient care. In its Vision, NETT {\textquoteleft}{\textquoteleft}will engage clinicians and providers at the front lines of emergency care to conduct large simple multi-center clinical trials to answer research questions of clinical importance{\textquoteright}{\textquoteright}. The NETT structure will be used to achieve economies of scale to facilitate cost-effective research, and is designed to conduct confirmatory phase III pivotal interventional trials in neurological emergencies. The CCC is at the University of Michigan and the Statistical and Data Management Center at Medical University of South Carolina (MUSC). NETT has created a {\textquoteleft}{\textquoteleft}Hub and Spoke{\textquoteright}{\textquoteright} research pattern that started with 11 hubs to which 6 more Hub sites were added recently. This infrastructure design permits a master agreement and avoids renegotiating common items in different research sites. Trials conducted in the NETT are funded competitively through independent R01 grant applications. These are initiated by investigators either within or outside the network and are developed collaboratively with the NETT. There are currently several funded phase III clinical trials, of which two are currently enrolling, and the others are preparing to enroll or are in the development phase. This includes, ALIAS: Albumin neuroprotection in acute ischemic stroke; RAMPART: prehospital treatment of status epilepticus with IV lorazepam or IM midazolam; ProTECT: progesterone neuroprotection in moderate or severe TBI; SHINE: Tight early glycemic control in ischemic stroke, and ARTIC: hypothermic neuroprotection in spinal cord injury.",
year = "2012",
month = feb,
doi = "10.1007/s12028-011-9610-z",
language = "English (US)",
volume = "16",
pages = "20--28",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "1",
}